以下文章来源于阿基米德Biotech ，作者阿基米德君 1月2 0日，历史上一个平淡的日子，唯一的热闹，可能是大寒之日上海飘雪。同日，另 一 场 寒 潮 却 无 声 无 息 ， 恒 生 生 物 科 技 指 数 （ HSHKBIO ） 成 交 额 跌 破 1 0 0 亿 港 币 ， 与 2 0 2 5年最高点相比下降近8 0 %，1 5家港股1 8A公司日成交额不足1 0 0万港币。 创新药在研发主战场外，正在开辟争夺流动性的第二战场。 技术和资本，一体两面，是创新药企的两大属性。早期生物科技没有自我造血功能，全 靠资本输血。成熟创新药企在每一个重要节点，跃升到更高发展阶段，也靠资本支持。 当前，通过港股1 8A通道上市的生物科技企业已达8 5家(含摘B)，还有超过8 0家递表排 队，而流动性却在指缝间溜走。自研能力不够硬，又不做市值管理的公司，等于自动退 出流动性争夺战，被边缘化，被遗忘，直至丧失融资能力。 阿基米德Biotech . 生物科技第三方独立观察，提前感知行业边际变化，客观中立，深入浅出，松弛愉悦 流动性。 作者 / 阿基米德君 来源 / 阿基米德Biotech （ID：ArchimedesBio ...

Summary of Key Points from the Conference Call Industry Overview - The conference call discusses the B7-H3 ADC (Antibody-Drug Conjugate) market, highlighting its potential in oncology treatments, particularly for prostate cancer and other solid tumors [1][3]. Company Insights - BioNTech has initiated the first Phase III clinical trial for BNT324 (DB-1311) targeting chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC), with results expected by January 2031 [1]. - DB-1311 has been licensed to BioNTech in 2023, marking it as the fifth B7-H3 ADC to enter Phase III trials, indicating significant global commercialization potential [1]. Clinical Data - DB-1311 is designed as a humanized anti-B7-H3 IgG1 monoclonal antibody with modifications to reduce ADCC/CDC effects, demonstrating high tumor selectivity and lower immunogenicity [2]. - In a study involving 68 heavily pre-treated mCRPC patients, DB-1311 achieved an overall response rate (ORR) of 42.3% and a 9-month progression-free survival (PFS) rate of 58.0%, with grade 3 or higher treatment-related adverse events (TRAE) at 28.9% [2]. - The drug also showed promising results in platinum-resistant ovarian cancer and cervical cancer, with ORRs of 58.3% and 43.3%, respectively, and median PFS of 8.2 and 7.0 months [2]. Market Potential - The global B7-H3 ADC market is projected to reach $2.4 billion by 2030 and expand to $14.1 billion by 2035, with the Chinese market expected to grow to $300 million by 2030 and $1.9 billion by 2035 [4]. - The first B7-H3 ADC is anticipated to receive approval around 2027, indicating a growing interest and investment in this therapeutic area [4]. Competitive Landscape - Major pharmaceutical companies, including Merck and GSK, have acquired B7-H3 ADC candidates from various biotech firms, indicating a competitive environment [3]. - Five B7-H3 ADC drugs are currently in Phase III clinical trials, with additional early-stage developments focusing on dual-targeting approaches to enhance treatment precision [3]. Research and Development Trends - The B7-H3 ADC research is highly active in China, with several local companies contributing to the pipeline of candidates entering late-stage clinical trials [2][3]. - B7-H3 is recognized for its dual role in promoting tumor growth through both immune and non-immune pathways, making it a focal point for research in various cancers [3].

Core Viewpoint - The company, Fuhong Hanlin (02696), has received approval from the National Medical Products Administration for clinical trials of a combination therapy involving HLX43, HLX07, and Surulitinib for the treatment of advanced solid tumors, which has positively impacted its stock price [1] Group 1: Company Developments - Fuhong Hanlin's stock rose over 4% in early trading, currently up 3.48% at HKD 56.5, with a trading volume of HKD 12.65 million [1] - The company plans to conduct Phase II clinical research for the combination therapy in China once conditions are met [1] Group 2: Product Information - HLX43 is a novel DNA topoisomerase I inhibitor conjugated with a self-developed PD-L1 targeting antibody, aimed at treating advanced/metastatic solid tumors [1] - HLX07 is an innovative biopharmaceutical developed by Fuhong Hanlin targeting the EGFR, also intended for advanced solid tumor treatment [1] - Surulitinib is an innovative anti-PD-1 monoclonal antibody developed by Fuhong Hanlin [1]

Summary of Key Points from Conference Call Company and Industry Involved - **Sarepta Therapeutics (SRPT)**: Focused on gene therapy for Duchenne Muscular Dystrophy (DMD) - **Revolution Medicines (RVMD)**: Involved in cancer therapeutics - **Cogent Biosciences**: Focused on targeted therapies for gastrointestinal stromal tumors (GIST) Core Insights and Arguments - **Sarepta's Clinical Trial Results**: - The company reported positive results from the Phase III EMBARK trial for its AAVrh74 gene therapy, Elevidys, used in DMD treatment - 52 patients treated for three years showed an improvement of 4.39 points in the NSAA score compared to the control group - Time to rise (TTR) decreased by 6.05 seconds - 10-meter walk/run time reduced by 2.7 seconds - These results contributed to an 8% increase in stock price [1][2] - **Revolution Medicines Stock Decline**: - The company experienced a 17% decline in stock price, potentially linked to failed acquisition negotiations with Merck [2] - **Cogent's FDA Breakthrough Therapy Designation**: - Cogent announced that its targeted therapy Bezuclastinib, which targets the D816V mutation of the KIT gene, received Breakthrough Therapy designation from the FDA - This designation is based on data from the Phase III PEAK trial for patients with imatinib-resistant GIST [2] Other Important but Possibly Overlooked Content - The positive results from Sarepta's trial may indicate a significant advancement in DMD treatment options, which could attract further investment and interest in the biotechnology sector - The decline in Revolution Medicines' stock may reflect broader market concerns or specific issues within the company, warranting further investigation into its financial health and strategic direction - The FDA's recognition of Cogent's therapy highlights the increasing focus on precision medicine and targeted therapies in oncology, which may influence future investment trends in the pharmaceutical industry [1][2]

Core Viewpoint - The company, Fuhong Hanlin (02696), has received approval from the National Medical Products Administration for clinical trials of a combination therapy involving HLX43, HLX07, and Surulitinib for the treatment of advanced solid tumors, leading to a stock price increase of over 4% in early trading [1]. Group 1: Company Developments - Fuhong Hanlin's stock price rose by 3.48% to HKD 56.5, with a trading volume of HKD 12.65 million [1]. - The company plans to conduct Phase II clinical research for the combination therapy in China once conditions are met [1]. Group 2: Product Information - HLX43 is a novel DNA topoisomerase I inhibitor conjugated with a PD-L1 targeting antibody, developed for treating advanced/metastatic solid tumors [1]. - HLX07 is an innovative biopharmaceutical developed by Fuhong Hanlin targeting the EGFR for advanced solid tumors [1]. - Surulitinib is an innovative anti-PD-1 monoclonal antibody developed by Fuhong Hanlin [1].

Company Overview: Lepu Biopharma (2157.HK) Industry Focus - The company operates in the biopharmaceutical industry, specifically focusing on oncology treatments, including immunotherapy, antibody-drug conjugates (ADC), and oncolytic virus therapies [1][2]. Key Points and Arguments R&D Pipeline and Product Development - Lepu Biopharma has developed a comprehensive pipeline of oncology products, covering three major areas: immunotherapy, ADC targeted therapy, and oncolytic virus drugs. The pipeline includes: - Already marketed PD-1 monoclonal antibody, Putilizumab, and MRG003 - Six ADC drugs, one introduced oncolytic virus, and one T cell engager (TCE) drug currently in clinical stages - The company is expected to enter a phase of new drug approvals over the next 3-5 years, indicating a robust pipeline [1][2]. Financial Performance - The company has achieved steady revenue growth driven by business development (BD) and sales, with a stable expense structure. - In the first half of 2025, Lepu Biopharma reported its first profit and positive operating cash flow [2]. Competitive Advantages of ADCs - MRG003 (EGFR ADC) has been approved for use in late-line nasopharyngeal carcinoma (NPC) in China, demonstrating superior survival benefits and safety compared to competitors. The drug is also being positioned for broader indications in head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC) [2][3]. - MRG004A (TF-ADC) for late-line pancreatic cancer has shown strong competitive potential and is currently in Phase III trials [2][3]. - MRG006A (GPC3 ADC) targets the liver cancer market and has shown promising results in Phase I trials, with plans to initiate Phase III trials in 2026 [3]. Oncolytic Virus Therapy - The company introduced the oncolytic virus therapy CG0070 in 2019, targeting the bladder cancer market. - CG0070 has initiated a rolling Biologics License Application (BLA) with the FDA for high-risk non-muscle invasive bladder cancer (NMIBC) and is undergoing critical registration bridging trials in China. The therapy has demonstrated the best historical durability of efficacy data in the NMIBC field, with a G3+ treatment-related adverse event (TRAE) rate of 0 [3]. International Expansion - The company has made progress in international collaborations with MRG007 (CDH17 ADC) and CTM012 (a tri-antibody targeting CD3/4-1BB/DLL3), enhancing its tumor immunotherapy output [3]. Revenue Projections - Lepu Biopharma is still in the investment phase for new drug development, with projected revenues of 880 million, 1.02 billion, and 1.49 billion yuan for 2025, 2026, and 2027, respectively, representing year-on-year growth rates of 138%, 16%, and 47%. The net profit attributable to the parent company is projected to be -20 million, 10 million, and 280 million yuan for the same years [3]. Risks - Potential risks include: - Delays in clinical progress of innovative drugs - Clinical data not meeting expectations - Sales performance of newly launched drugs falling short - Geopolitical risks [4].

Summary of the Conference Call for Lepu Biopharma (2157.HK) Company Overview - Lepu Biopharma is focused on the development of innovative cancer therapies, particularly in the areas of immunotherapy, antibody-drug conjugates (ADC), and oncolytic virus drugs. The company has a robust pipeline and is expected to enter a period of new drug approvals in the next 3-5 years [1][2]. Key Points R&D Pipeline and Drug Approvals - The company has developed multiple oncology product lines, including: - PD-1 monoclonal antibody, Pralsetinib, and MRG003, which are already on the market. - Six ADC drugs, one oncolytic virus, and one T cell engager (TCE) drug currently in clinical stages. - The overall pipeline is well-structured, indicating a promising future for new drug approvals [1][2]. Financial Performance - The company has achieved its first profitability and positive operating cash flow in the first half of 2025, driven by business development (BD) and sales efforts [2]. Competitive Advantages of ADCs 1. **MRG003 (EGFR ADC)**: - Approved for use in late-line nasopharyngeal carcinoma (NPC) in China, showing superior survival benefits and safety compared to competitors. - Actively pursuing broader indications in head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC), with a Phase III trial ongoing for 2L+ HNSCC [2][3]. 2. **MRG004A (TF-ADC)**: - Currently in Phase III trials for late-line pancreatic cancer, demonstrating strong competitive potential [3]. 3. **MRG006A (GPC3 ADC)**: - A first-in-class (FIC) targeting the liver cancer market, with promising results from Phase I trials, and expected to enter Phase III trials in 2026 [3]. 4. **CMG901**: - A global FIC CLDN 18.2 ADC, currently in Phase III trials [3]. 5. **MRG001 (CD20 ADC)**: - Showing potential in diffuse large B-cell lymphoma (DLBCL) [3]. Oncolytic Virus Therapy - The company introduced the oncolytic virus therapy CG0070 in 2019, targeting the bladder cancer market. - CG0070 has initiated a rolling Biologics License Application (BLA) with the FDA for high-risk non-muscle invasive bladder cancer (NMIBC) and is in critical registration bridging trials in China. - Recent Phase III data indicates historical best durability in NMIBC, with a G3+ treatment-related adverse event (TRAE) rate of 0, showcasing both efficacy and safety [3]. International Expansion - The company has successfully collaborated on international projects with MRG007 (CDH17 ADC) and CTM012 (a tri-antibody targeting CD3/4-1BB/DLL3) [3]. Revenue Projections - Revenue forecasts for the company are as follows: - 2025: 880 million CNY - 2026: 1.02 billion CNY - 2027: 1.49 billion CNY - Expected growth rates are 138% in 2025, 16% in 2026, and 47% in 2027, with net profits projected at -20 million CNY in 2025, 10 million CNY in 2026, and 280 million CNY in 2027 [3]. Investment Rating - The company’s ADC pipeline is progressing steadily, and commercial advancements are on track, leading to a "Buy" rating [4]. Risk Factors - Potential risks include: - Delays in clinical progress of innovative drugs. - Subpar clinical data for innovative drugs. - Poor sales performance post-launch of innovative drugs. - Geopolitical risks [4].

Core Viewpoint - The company is entering a new drug approval phase with a well-structured pipeline in oncology, focusing on immunotherapy, ADC targeted therapy, and oncolytic virus drugs, which is expected to yield multiple new drug approvals in the next 3-5 years [1][2]. Pipeline Development - The company has developed multiple oncology products, including two already marketed drugs (PD-1 monoclonal antibody Prutilizumab and MRG003) and has six ADC drugs, one oncolytic virus, and one TCE drug in clinical stages [1]. - MRG003 (EGFR ADC) has been approved for post-line NPC in China, showing superior survival benefits and safety compared to competitors, with ongoing trials for HNSCC and NSCLC [1]. - MRG004A (TF-ADC) for post-line pancreatic cancer is currently in Phase III trials after demonstrating strong competitive advantages in Phase I [2]. - MRG006A (GPC3 ADC) is targeting the liver cancer market, with promising results in Phase I trials and plans to initiate Phase III trials in 2026 [1][2]. Oncolytic Virus Therapy - The company has introduced the oncolytic virus therapy CG0070 for bladder cancer, which is currently undergoing a rolling BLA application with the FDA and is in critical registration bridging trials in China [2]. - CG0070 has shown the best historical durability efficacy data in the NMIBC field, with a G3+TRAE rate of 0, indicating excellent efficacy and safety [2]. Financial Projections - The company is still in the investment phase for innovative drug development, with projected revenues of 880 million, 1.02 billion, and 1.49 billion yuan for 2025, 2026, and 2027, respectively, representing year-on-year growth of 138%, 16%, and 47% [2]. - The net profit attributable to the parent company is expected to be -20 million, 10 million, and 280 million yuan for the same years [2]. Investment Recommendation - The company is rated as a "buy" due to the steady progress of its ADC pipeline and successful commercialization efforts [2].

消息面上，据石药集团官微消息，近日，由石药集团与江苏康宁杰瑞生物制药有限公司合作开发的安尼 妥单抗(KN026)针对HER2阳性胃癌/胃食管结合部腺癌患者的III期临床研究结果成功发表于肿瘤学领域 顶级期刊《肿瘤学年鉴》(Annals of Oncology，IF：65.4)。这是一项随机、双盲、对照、多中心的III期 临床研究，旨在评估安尼妥单抗联合化疗对比标准治疗在既往一线含曲妥珠单抗治疗失败的HER2阳性 胃癌/胃食管结合部腺癌患者中的疗效和安全性。 智通财经APP获悉，石药集团(01093)涨超5%，截至发稿，涨5.14%，报10.44港元，成交额4.99亿港元。 ...

Group 1 - Approval Status: HLX43 (a PD-L1 targeted antibody-drug conjugate) in combination with HLX07 (an anti-EGFR monoclonal antibody) and Hansizhuang (Sruvelizumab) has received approval from NMPA for clinical trials aimed at treating advanced solid tumors in China [1] Group 2 - R&D Progress: Phase 1/2 clinical trials for HLX43 are being conducted in multiple regions including China, the United States, and Japan, covering indications such as NSCLC, colorectal cancer, cervical cancer, and esophageal squamous cell carcinoma [2] - Clinical Data: In patients with previously treated NSCLC, the overall response rate (ORR) reached 37.0% and the disease control rate (DCR) was 87.0%; for cervical cancer patients, the ORR was 41.4% (with the 3.0 mg/kg dosage group achieving 70%) [2] - Market Position: There are currently no similar combination therapies approved for marketing globally [2]